Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Array BioPharma, Inc., Foundation Medicine, Inc., Merck Sharp & Dohme Corp., NewLink Genetics, Novartis Pharmaceuticals Corporation, and Prometheus Laboratories Inc.

Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

Release Date: April 30, 2018
Expiration Date: April 30, 2019
Media: Internet - based


Activity Overview

Community Practice Connections™ 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® highlights current and developing therapies for patients with melanoma and Merkel cell carcinoma, including targeted therapy and immune checkpoint inhibitors. The management of skin cancer and other cutaneous malignancies has radically changed in recent years, in both the advanced and adjuvant disease settings. These changes have been paradigm-changing and great news for your patients, but they have also created educational gaps particularly for community practitioners who face the continuous challenge of staying abreast of vital issues relevant to their clinical practices. Through clinical vignettes and short interviews addressing key questions, you will hear directly from top experts in melanoma and other cutaneous malignancies on the appropriate use and sequencing of recently approved agents, companion diagnostic tests, findings from key clinical trials, updates made to treatment guidelines and recommendations, and clinical trial availability.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Array BioPharma, Inc., Foundation Medicine, Inc., Merck Sharp & Dohme Corp., NewLink Genetics, Novartis Pharmaceuticals Corporation, and Prometheus Laboratories Inc.

Table of Contents

  • Module 1: Current and Emerging Treatment Strategies in Cutaneous Malignancies
  • Module 2: Treatment Options in Advanced Melanoma and Post‒PD-1 Failure
  • Module 3: Unmet Needs in Melanoma (Mucosal, Ocular, and CNS Disease)

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, fellows, surgical oncologists, and radiation oncologists who treat patients with skin and other cutaneous malignancies. Dermatologists, dermatopathologists and pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of melanoma and other cutaneous malignancies will be invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Discuss the latest clinical trial evidence on current and emerging treatment strategies across cutaneous malignancies, including regional, immuno-, and targeted therapies
  2. Demonstrate the impact of multidisciplinary approaches for the identification and management of treatment-related toxicities in patients with cutaneous malignancies
  3. Detail the evolving use of biomarkers and other methods to personalize care across treatment settings for patients with melanoma and other cutaneous malignancies
  4. Place recent and emerging trial evidence in the context of changing treatment paradigms in order to optimally sequence therapies in the management of melanoma, basal cell carcinoma, Merkel cell carcinoma, and other cutaneous malignancies

Faculty, Staff, and Planners' Disclosures


Omid Hamid, MD
Chief, Translational Research and Immuno-Oncology
Director, Cutaneous Malignancies,
The Angeles Clinic and Research Institute
Director of Experimental Therapeutics,
Cedars Sinai Medical Care Foundation
Los Angeles, CA

Disclosure:Grant Research Support: Astra Zeneca, BMS, Celldex, Genentech, Immunocore, Incyte, Merck, Merck Serano, MedImmune, Novartis, Pfizer, Rinat, Roche; Consultant: Amgen, Novartis, Roche, BMS, Merck; Speakers Bureau: BMS, Genentech, Novartis, Amgen

Jeffrey S. Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, NY

Disclosure: Grant Research Support: BMS, GSK, Merck, Incyte, Genentech all to Moffitt; Consultant: BMS, GSK, Merck, Incyte, Genentech, AstraZeneca, Meddivation; Shareholder: Altor, Celldex, cCAM, CytomX; Other: Named on a patent held by Moffitt that relates to a predictive marker for ipilimumab

Jason J. Luke, MD, FACP
Assistant Professor of Medicine
The University of Chicago Medicine
Chicago, IL

Disclosure: Consultant: Amgen, Array, Check-Mate, Benevir, BMS, EMD Serono, Merck (unpaid)

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By